论文部分内容阅读
目的分析乳腺癌分子分型的年龄分布及Ki-67表达的影响因素。方法选取乳腺癌患者340例,将其分为<40岁年龄组(87例)、40~60岁年龄组(185例)和>60岁年龄组(68例)。收集包含肿瘤组织的雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子(Her-2)和肿瘤细胞增殖相关核抗原Ki-67的病理资料,并进行分子分型,分析乳腺癌分子分型的年龄分布和Ki-67表达与乳腺癌临床病理特点的关系。结果 >60岁年龄组中Luminal A型所占比例明显高于其他两组(P<0.05),40~60岁年龄组中Luminal B型所占比例明显高于其他两组(P<0.05),<40岁年龄组三阴型所占比例明显高于其他两组(P<0.05),Ki-67的表达与患者年龄、ER/PR和Her-2的表达和分子分型均相关(P<0.05)。结论不同年龄组乳腺癌患者的分子亚型和Ki-67表达存在差异,各有不同的临床病理特征,临床上应据此制定个性化治疗方案及进行预后风险的评估。
Objective To analyze the age distribution of breast cancer molecular typing and the influencing factors of Ki-67 expression. Methods A total of 340 patients with breast cancer were selected and divided into the following groups: <40 years old (87 cases), 40-60 years old (185 cases) and> 60 years old (68 cases). The pathological data of tumor tissues including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor (Her-2) and tumor cell proliferation-associated nuclear antigen Ki-67 were collected and subjected to molecular typing, To analyze the age distribution of breast cancer molecular typing and the relationship between Ki-67 expression and clinicopathological features of breast cancer. Results The percentage of Luminal A type in the 60-year-old group was significantly higher than that in the other two groups (P <0.05). The proportion of Luminal B in the 40-60-year age group was significantly higher than that in the other two groups (P <0.05) The proportion of trigeminal type in the 40-year-old group was significantly higher than that in the other two groups (P <0.05). Ki-67 expression was correlated with the age, ER / PR and Her-2 expression and molecular typing 0.05). Conclusion There are differences in the molecular subtypes and Ki-67 expression in breast cancer patients of different age groups, each with different clinicopathological features. In accordance with this, we should formulate a personalized treatment plan and evaluate the prognosis risk.